Trial Profile
A Phase 1, 3 Part, Randomized, Placebo Controlled, Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Meplazumab and to Assess Its Antimalarial Activity Against Plasmodium Falciparum in a Malaria Challenge Model in Healthy Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Meplazumab (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pacific Meinuoke Biopharmaceutical
- 19 Sep 2023 Status changed from not yet recruiting to withdrawn prior to enrolment because the same drug has completed the phase I and II clinical trials for COVID-19.
- 04 Jan 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 04 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.